15:54 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Kymera raises $65M series B

Protein degradation company Kymera Therapeutics LLC (Cambridge, Mass.) closed an untranched $65 million series B round on Nov. 13 to bring its lead program into the clinic. Kymera is developing heterobifunctional molecules that bind to...
16:25 , Nov 13, 2018 |  BioCentury  |  Finance

Kymera’s degradation toolbox

As the protein degradation space continues to gain traction, Kymera Therapeutics LLC has attracted interest from investors to the tune of $65 million to bring its first program to the clinic. 6 Dimensions Capital, Bessemer...
12:03 , Nov 13, 2018 |  BC Extra  |  Financial News

Kymera raises $65M series B

Protein degradation company Kymera Therapeutics LLC (Cambridge, Mass.) closed an untranched $65 million series B round to bring its lead program into the clinic. Kymera is developing heterobifunctional molecules that bind to both an E3...
18:36 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Decibel raises $55M in series C, names Scangos chairman

Decibel Therapeutics Inc. (Boston, Mass.) raised $55 million on June 19 in a series C round from existing investors Third Rock Venture, GV, SR One and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and new investors Foresite Capital,...
22:01 , Jun 19, 2018 |  BC Extra  |  Financial News

Decibel raises $55M in series C, names Scangos chairman

Decibel Therapeutics Inc. (Boston, Mass.) raised $55 million in a series C round from existing investors Third Rock Venture, GV, SR One and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and new investors Foresite Capital, Bessemer Venture Partners,...
19:51 , Oct 13, 2017 |  BC Week In Review  |  Financial News

Allena proposes $92M IPO

Kidney disease company Allena Pharmaceuticals Inc. (Newton, Mass.) proposed to raise up to $92 million on Oct. 6 in an IPO on NASDAQ underwritten by Credit Suisse, Jefferies, Wedbush and Cowen. Allena's lead candidate, ALLN-177...
19:53 , Oct 9, 2017 |  BC Extra  |  Financial News

Allena proposes $92M IPO

Kidney disease company Allena Pharmaceuticals Inc. (Newton, Mass.) proposed to raise up to $92 million in an IPO on NASDAQ underwritten by Credit Suisse, Jefferies, Wedbush and Cowen. Allena's lead candidate, ALLN-177 , is an...
02:35 , Dec 10, 2015 |  BC Extra  |  Financial News

Allena's series C round brings $53M

Allena Pharmaceuticals Inc. (Newton, Mass.) raised $53 million in a series C financing led by Partner Fund Management. New investors Fidelity and Wellington Management also participated, along with existing investors Frazier Healthcare, HBM BioCapital and...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Financial News

Bessemer Venture Partners financial update

BVP’s portfolio includes endocrine and metabolic play Allena Pharmaceuticals Inc. (Newton, Mass.); neuromuscular company Flex Pharma Inc. (NASDAQ:FLKS, Boston, Mass.); and kidney and vascular disease play Proteon Therapeutics Inc. (NASDAQ:PRTO, Waltham, Mass.). Bessemer Venture Partners...
02:18 , Feb 20, 2015 |  BC Extra  |  Financial News

Bessemer unveils $1.6B fund

Bessemer Venture Partners raised $1.6 billion for its BVP IX fund, which the firm will invest in several sectors including therapeutics and healthcare IT. BVP's portfolio includes endocrine and metabolic play Allena Pharmaceuticals Inc. (Newton,...